




Febuxostat

Revised: November 15, 2023.

CASRN: 144060-53-7



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of febuxostat during breastfeeding. Because febuxostat is more than 99% bound to plasma proteins, the amount in milk is likely to be low. Furthermore, oral bioavailability is only about 50%, so the amount an infant receives systemically is expected to be very small. If febuxostat is required by the mother, it is not a reason to discontinue breastfeeding; however, until more data become available, an alternate drug may be preferred.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Allopurinol, Probenecid

Substance Identification

Substance Name

Febuxostat

CAS Registry Number

144060-53-7

Drug Class

Breast Feeding

Lactation

Milk, Human

Antigout Agents

Gout Suppressants